Denosumab in castration-resistant prostate cancer

The Lancet

Volumn 379, Issue 9828, 2012, Pages

  Kyrgidis, Athanassios ^a   Tzellos, Thrasivoulos George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB;

BONE METASTASIS; CASTRATION RESISTANT PROSTATE CANCER; FOLLOW UP; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; LETTER; METASTASIS FREE SURVIVAL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR;

ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RANK LIGAND;

EID: 84860827142     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60764-8     Document Type: Letter

References (5)

1. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 39-46.
2. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999;319: 1492-95.
3. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009; 67 (suppl 1): 2-12.
4. Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009; 27: 5356-62.
5. Kyrgidis A, Tzellos T-G, Toulis K, Antoniades K. The facial skeleton in patients with osteoporosis: a field for disease signs and treatment complications. J Osteopor 2011; published online Feb 16. DOI: 10.4061/2011/147689.